Metabotropic glutamate receptor 3 is involved in B-cell-related tumor apoptosis

Liu, Xiaoling; Zhang, Yu; Wang, Zhiding; Wang, Xiaoqian; Zhu, Gaizhi; Han, Gencheng; Chen, Guojiang; Hou, Chunmei; Wang, Tianxiao; Shen, Beifen; Li, Yan; Ma, Ning; Xiao, He; Wang, Renxi

doi:10.3892/ijo.2016.3623

Cited by 17 publications

(16 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, downregulation of GRM3 was observed in tumour tissues and correlated with a shorter survival of RCC patients, whereas GRM4 overexpression was found in tumours and correlated with poor survival. Consistent with our findings, it has been shown that GRM3 mediates B‐cell‐related tumour cell apoptosis via forkhead box O1, and GRM3 deficiency promotes tumour progression . Mounting evidence has also revealed that GRM4 overexpression is correlated with poor prognosis in various cancers such as osteosarcoma, colorectal cancer, and glioma .…”

Section: Discussionsupporting

confidence: 91%

Clinical significance of glutamate metabotropic receptors in renal cell carcinoma risk and survival

et al. 2018

View full text Add to dashboard Cite

Accumulating evidence suggests the roles of glutamate metabotropic receptors (GRMs) in cancer, in addition to synaptic signalling. The present study assessed the associations of genetic variants in eight GRM genes with regard to risk and overall survival (OS) in 780 renal cell carcinoma (RCC) patients and controls. After adjustment for known risk factors, GRM5 rs7102764 T was associated with an increased risk of RCC (P = 0.006). Additional analysis has provided evidence that rs7102764 T was correlated with a higher expression of GRM5, which is consistently found to be upregulated in tumours, compared to normal tissues. Furthermore, the GRM3 rs701332 C, GRM4 rs2499707 T, and GRM4 rs4713742 T alleles were significantly associated with a poorer OS (P ≤ 0.030). The three loci were also observed to have strong cumulative effects on OS. Additional analysis has revealed a significant genotype‐expression correlation of rs2499707 T with increased GRM4 expression, which in turn leads to poorer OS in patients with RCC. GRMs might be involved in RCC development and progression, and genetic variants in GRMs might be promising biomarkers.

show abstract

Section: Discussionsupporting

confidence: 91%

Clinical significance of glutamate metabotropic receptors in renal cell carcinoma risk and survival

et al. 2018

View full text Add to dashboard Cite

show abstract

“…This may explain the prognostic role of EIF4EBP1 in MM, which, to the best of our knowledge, has not been reported previously. FOXO1 has been reported to act as a tumor suppressor for MM (76). The activation of FOXO1 could subsequently inhibit the tumor growth and induce cell autophagy and cell death (77)(78)(79)(80).…”

Section: Discussionmentioning

confidence: 99%

A predicted risk score based on the expression of 16 autophagy‑related genes for multiple myeloma survival

Zhu¹,

Wang

Zeng³

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Autophagy has an important role in the pathogenesis of plasma cell development and multiple myeloma (MM); however, the prognostic role of autophagy-related genes (ARGs) in MM remains undefined. In the present study, the expression profiles of 234 ARGs were obtained from a Gene Expression Omnibus dataset (accession GSE24080), which contains 559 samples of patients with MM analyzed with 54,675 probes. Univariate Cox regression analysis identified 55 ARGs that were significantly associated with event-free survival of MM. Furthermore, a risk score with 16 survival-associated ARGs was developed using multivariate Cox regression analysis, including ATIC,

show abstract

“…Metabolic glutamate receptor 3 (GRM3) is an inhibitory molecule on the surface of B cells and a subtype of metabolic glutamate receptor group II. It is a G protein-coupled receptor that can inhibit growth of mouse myeloma cell line SP 2/0 [19] . The genetic abnormalities of GRM3 were also often described in renal cell carcinoma and esophageal cancer.…”

Section: Discussionmentioning

confidence: 99%

Identification of differentially expressed genes in Cushing's disease by integrated bioinformatics analysis

Lv¹,

Yu²,

Ren³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Cushing's disease is a rare and little-known disease, and the individualization of drug treatment varies greatly. Studies have shown that the gene expression profile of Cushing's disease is related to its clinical characteristics. Therefore, the study aims to identify key differential genes between the age and size of tumors through bioinformatics technology, thus providing a theoretical basis for personalized targeted therapy of Cushing's disease. Methods Downloading the gene expression microarray (GSE93825) data from the Gene Expression Omnibus (GEO) database and obtaining differentially expressed genes (DEGs) of different tumor sizes and ages through GEO2R. The DAVID database, Cytoscape and String platforms were utilized for functional enrichment analysis and protein-protein interaction (PPI) network analysis on selected differential genes. Results First, 96 DEGs were identified between macroadenoma (MAC) and microadenoma (MIC), which initially proved the different gene expression characteristics between them. Second, a total of 2128 DEGs were identified in MAC age group. The top five hub genes of the PPI network were GNGT2, LPAR3, PDYN, GRM3, and HTR1D. A total of 16 DEGs were identified in MIC age group. In addition, 88 DEGs were identified in younger MAC and MIC groups. The top five hub genes included LEP, PTGS2, STAT6, CXCL12, and ITPKB. 299 DEGs were identified in senior MAC and MIC groups. The first five hub genes were CCR7, LPAR2, CXCR5, ADCY3, and TAS2R14. By virtue of DAVID and Cytoscape software, the function enrichment analysis and core module analysis were performed successfully. Conclusions In summary, our research shows through bioinformatics analysis that different gene expression profiles of Cushing's disease are related to the size and age of the tumor, which may provide new insights into the molecular pathogenesis of Cushing's disease. These hub genes may be used for accurate diagnosis and treatment of Cushing's disease.

show abstract

Metabotropic glutamate receptor 3 is involved in B-cell-related tumor apoptosis

Cited by 17 publications

References 43 publications

Clinical significance of glutamate metabotropic receptors in renal cell carcinoma risk and survival

Clinical significance of glutamate metabotropic receptors in renal cell carcinoma risk and survival

A predicted risk score based on the expression of 16 autophagy‑related genes for multiple myeloma survival

Identification of differentially expressed genes in Cushing's disease by integrated bioinformatics analysis

Contact Info

Product

Resources

About